Skip to content
Invest in intelligence that delivers
Client Portal
Physician Portal
Home
Market Expertise
Offering
About
Thought Leadership
Media
Menu
Home
Market Expertise
Offering
About
Thought Leadership
Media
Contact
Search
Search
Close this search box.
Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report
From: Multiple Sclerosis News Today
By: Alice Melao
Media Coverage
,
Neurology
Sign up for alerts, market insights and exclusive content in your inbox.
Subscribe
Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:
HEMATOLOGY
Throughout 2024, we will be publishing over
10 groundbreaking studies
covering a wide range of indications within classical hematology.